Puig Lluís, Lomaga Mark, Hollister Kristin, Dutronc Yves, Berggren Lovisa, van de Kerkhof Peter C M
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, ES-08041 Barcelona, Spain. E-mail:
Acta Derm Venereol. 2020 Dec 9;100(19):adv00344. doi: 10.2340/00015555-3700.
Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806). Patient-reported outcomes investigated included patient global assessment, pruritus, skin pain, health-related quality of life, and work productivity. Ixekizumab-treated patients reported greater improvements in patient-reported outcomes sooner after treatment compared with ustekinumab-treated patients, and maintained greater improvements in patient global assessment scores (ixekizumab 0.72, ustekinumab 1.19; p < 0.001), rates of Dermatology Life Quality Index (0, 1) (ixekizumab 71.3%, ustekinumab 56.6%, p < 0.01), and 36-item Short-form Health survey physical component summary score change from baseline (ixekizumab 5.53, ustekinumab 3.28; p < 0.05) at week 52. While clinically meaningful improvements in patient-reported outcomes resulted with either treatment, ixekizumab provided more rapid improvements in patient-reported outcomes and superior outcomes for some assessments through one year of treatment, while maintaining statistically superior improvements in skin severity, as assessed by either physicians or patients.
患者报告的结局对于评估新的银屑病治疗方法很有价值。本研究调查了中度至重度斑块状银屑病患者使用依奇珠单抗或乌司奴单抗按照各自的标签给药52周（IXORA-S-NCT02561806）后的患者报告结局。所调查的患者报告结局包括患者整体评估、瘙痒、皮肤疼痛、健康相关生活质量和工作效率。与接受乌司奴单抗治疗的患者相比，接受依奇珠单抗治疗的患者在治疗后更快地报告了患者报告结局的更大改善，并且在患者整体评估评分（依奇珠单抗0.72，乌司奴单抗1.19；p<0.001）、皮肤病生活质量指数（0，1）的比率（依奇珠单抗71.3%，乌司奴单抗56.6%，p<0.01）以及第52周时36项简短健康调查身体成分总结评分相对于基线的变化（依奇珠单抗5.53，乌司奴单抗3.28；p<0.05）方面保持了更大的改善。虽然两种治疗均带来了临床上有意义的患者报告结局改善，但依奇珠单抗在患者报告结局方面提供了更快的改善，并且在长达一年的治疗中，对于某些评估具有更好的结局，同时在医生或患者评估的皮肤严重程度方面保持了统计学上更优的改善。
